Leber Congenital Amaurosis Market Size and Trends

The Global Leber Congenital Amaurosis Market is estimated to be valued at USD 1.29 Bn in 2025 and is expected to reach USD 1.78 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.7% from 2025 to 2032.

Leber Congenital Amaurosis Market Key Factors

To learn more about this report, Request sample copy

Increasing prevalence of inherited retinal diseases

The prevalence of inherited retinal diseases is increasing at an alarming rate across the globe. Leber congenital amaurosis, being one form of inherited retinal dystrophy, is also witnessing a spike in cases year-over-year. As per some estimations, around 2-3 out of every 100,000 live births are diagnosed with LCA. Given that the global birth rate averages around 140 million newborns annually, it means around 2,800 to 4,200 new LCA cases are emerging each year.

This upward trend can majorly be attributed to the advancing age of prospective parents. Medical science has enabled people to delay parenthood till late 30s or early 40s now unlike earlier times when most people had kids in their 20s. However, it is a well-established fact that the likelihood of inherited genetic disorders and mutations increase with increasing parental age. Studies have shown advanced paternal age to be a significant risk factor for several inherited eye diseases including LCA. Since more people are opting to become parents at an older age nowadays due to social and economic reasons, the chances of their offspring inheriting genetic retinal conditions like LCA grow correspondingly.

Another important reason for the rise in inherited retinal dystrophy prevalence is improving diagnosis. Availability of advanced genetic testing tools and techniques allows for faster and more definitive diagnosis of even rare retinal disorders. Previously, conditions like LCA which manifest from childhood often went undiagnosed for years due to the lack of expertise and diagnostic limitations. But now sophisticated genetic screening methods enable diagnosis even in newborn babies showing first signs of visual impairment. This has led to more accurate disease surveillance worldwide. Also, growing awareness about these genetic conditions thanks to patient advocacy groups is encouraging more families to go for diagnostic screening of family members, leading to identification of new cases.